A clinical-trial number can make an online claim feel settled. It links to a government website, lists investigators and endpoints, and gives the project an official-looking identity. Yet a registration can describe a question nobody has answered publicly.
The useful skill is to follow the question from its original plan to its reported results, then ask how far those results travel. That works for an experimental peptide with a tiny pilot study and for a medicine supported by a large trial. The size of the claim should remain attached to the evidence behind it.
Registration is a starting point
ClinicalTrials.gov is a registry and results database. A listing is not a government endorsement of the intervention: the U.S. National Library of Medicine has explicitly explained that inclusion does not mean a study has been evaluated by the federal government. NLM’s explanation of the registry
Look at what the record actually says. Estimated enrollment is a plan, not a count of people who completed follow-up. A planned completion date is not evidence that completion occurred. “Completed” describes a study’s status; it does not tell you whether the treatment worked. A results table, a journal paper, and a regulatory decision are further pieces of the record.
A concrete example is the BPC-157 record NCT02637284. As checked on October 21, 2026, it described a phase 1 safety and pharmacokinetics study with estimated enrollment of 42, unknown current status, and no posted results. The record establishes that such a study was registered. It cannot establish what happened to participants or provide an efficacy result. The BPC-157 study record
Missing public results are a limit on what a reader can conclude. They are not a favorable result, and they do not prove that the treatment failed. The honest entry in the evidence column is “outcome not established from this record.”
Match the paper to the question
When results are available, start with who was studied, what was compared, and what counted as success. The SELECT trial of semaglutide, registered as NCT03574597, provides a useful example. Its registry describes a randomized comparison with placebo and a primary cardiovascular outcome combining cardiovascular death, nonfatal heart attack, and nonfatal stroke. The SELECT study record
SELECT enrolled 17,604 adults aged at least 45 who had established cardiovascular disease and overweight or obesity, without diabetes. Those eligibility criteria are part of the result’s meaning. They do not describe every person curious about metabolic health. SELECT’s enrollment and eligibility record
A comparison group matters because outcomes can change without the experimental treatment. Random assignment helps make the groups comparable at the beginning. Blinding helps reduce differences caused by expectations and treatment knowledge. Neither feature makes a trial perfect, but both make a causal interpretation more credible than a collection of testimonials.
Also read the endpoint literally. A composite groups several events together. A favorable composite does not automatically establish the same benefit for each component. Improved laboratory values, reduced symptoms, and fewer serious clinical events are likewise different outcomes. An article should name the one the study actually measured.
Put relative and absolute results together
FDA’s approval summary reports SELECT’s primary event in 6.5% of participants assigned semaglutide and 8.0% assigned placebo. The event proportions differ by 1.5 percentage points. FDA’s account of the trial
The publication reports a hazard ratio of 0.80, with a 95% confidence interval from 0.72 to 0.90 and mean follow-up of 39.8 months. That ratio summarizes the relative event hazard over follow-up; it is not a 20-percentage-point reduction in the number of participants experiencing an event. Keeping both measures visible prevents a large relative headline from replacing the practical size of the observed difference. SELECT’s published results
Time belongs alongside the numbers. A result accumulated over several years does not describe the chance of benefit next week. The confidence interval also matters: a point estimate is an estimate with uncertainty, rather than a precisely known effect that will repeat identically in every setting.
Read the harms with the same attention
SELECT reported adverse events leading to permanent discontinuation in 16.6% of the semaglutide group and 8.2% of the placebo group. That is an outcome relevant to tolerability, alongside the cardiovascular benefit. It does not mean that every discontinuation was a serious adverse event, or that discontinuation captures every possible harm. The primary trial report
Ask how harms were collected and how many people remained under observation. Missing follow-up can make a tidy result harder to interpret. The CONSORT 2025 reporting standard calls for transparent accounts of trial methods, participant flow, outcomes, and harms. Its checklist is useful to readers as well as researchers: an omission is a reason to investigate, not an invitation to assume the most reassuring answer. CONSORT 2025
Finally, find the regulatory decision itself. In March 2024, FDA approved a specific cardiovascular-risk-reduction indication for Wegovy in adults with cardiovascular disease and obesity or overweight. That was an identifiable decision about a particular product and use, beyond registration or publication. It was not an approval of every product containing semaglutide, every proposed use, or peptides as a category. FDA’s approval announcement
A strong reading ends with a bounded claim: this intervention produced this result, compared with this alternative, in these people, over this period, with these observed harms and uncertainties. When a promotional sentence drops those boundaries, return to the trial and put them back.
A thought worth keeping?
